Fig. 2
From: Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer
Lasofoxifene reduced lung and liver metastases. a Representative areas of IHC staining with human cytokeratin AE1/AE3 showing lung metastases (brown). b Percent of metastasis area normalized to total lung area (n = 4–5). *p < 0.05, **p < 0.005 by Student t-test. c Representative H&E staining of livers. d Percent metastasis area normalized to total liver area (n = 3–5). *p < 0.05, **p < 0.005 by Student t-test for Y537S; §p = 0.05 by Fisher’s exact test for D538G. F, fulvestrant; L1, L5, and L10, lasofoxifene at 1, 5, and 10 mg/kg; V, vehicle